Skip to main content
Equibles
HEPA logo

HEPA · Hepion Pharmaceuticals, Inc.

Track HEPA — free

Use HEPA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HEPA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.14 -0.18 (-57.55%) At close · May 13
Rebalance outlook locked
Going-concern doubt — flagged Aug 13, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Due to our recurring and expected continuing losses from operations, we have concluded there is substantial doubt in our ability to continue as a going concern within one year of the issuance of these condensed consolidated financial statements without additional capital becoming available to us.”
View the 10-Q filed Aug 13, 2026
Market Cap
$6.77M
Shares
90.22M
Volume · May 13 1.91M Avg daily vol (40 sessions) 7.18M

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.14 Open$0.15 Day$0.11–0.22 52W close$0.14–65.00 Avg vol 30d8.5M Short int1K · 0.0% float · 1.0d Short vol1% DataJan 2020–May 2025 Filing10-Q · Aug 13

Up next

Latest filing: 10-Q
filed Aug 13, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$3.19M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 896.3%
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.63M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+42.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
—
Latest settlement
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −99%
below
Price vs 50-day avg −86%
below
RSI (14) 22
oversold
MACD trend Positive
52-week position 0%
near low
Momentum
relative strength
Very Weak
1-month return −65%
trailing
6-month return −100%
trailing
YTD return −99%
this year
Relative strength −100%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $21 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Accumulating
Net +$835.0K over 90 days · 0% sells
Short interest Falling
0.00% of float · ▼ -83.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Fundamentals
Strong
EPS growth +99%
Y/Y
Free cash flow $-3.3M
Balance sheet $1.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 162%
annualized · 1-yr
Max drawdown −100%
past year
ATR 116.4%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−99% Bearish
Price vs 50-day avg
−86% Bearish
RSI (14)
22 Neutral
MACD trend
Positive Bullish
52-week position
0% Bearish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $21 — 200d above 50d
Institutional flow Flat
0% holders QoQ
Insider flow Accumulating
Net +$835.0K over 90 days · 0% sells
Short interest Falling
0.00% of float · ▼ -83.7% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
1 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $0 Now $0 · 0% Range high $65
vs 200-day avg -99% vs 50-day avg -86%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
HEPA
Hepion Pharmaceuticals, Inc.
this stock
$6.77M — — — 0.0%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders
Holders
1
% held
0.0%
Net QoQ
0 sh
Top holder
Ancora Advisors LLC
Held Float
View
Short & Settlement
Short Interest Falling
Shares short
1.5K
Days to cover
1.0d
Change
-7.6K sh
View
Short Volume
Short vol %
1%
As of
Aug 21, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$0
As of
Jul 9, 2026
View
Off-Exchange
Off-exchange %
71.3%
Week of
May 12, 2025
Off-exch Lit
View
Smart Money
Insider Trades Cluster buy
Net (90d)
+$835.0K
Buyers / Sellers
6 / 0
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-8.3M
EPS diluted
$-0.88
View
Filings
SEC Filings
Latest
8-K
Filed
Oct 9, 2026
This year
20
View
Exempt Offerings
Offering
$3.1M
Filed
Aug 5, 2026
View

Performance

5D 20D 120D MTD YTD
HEPA -58.3% -64.9% -99.6% -53.3% -99.4%
SPY +5.0% +8.9% +0.2% +5.8% +0.1%
vs SPY -63.4% -73.8% -99.8% -59.1% -99.6%
Key facts CIK 1583771 CUSIP 426897401 Visit website Investor relations